3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
20
Lung Neoplasms
9
Small Cell Lung Carcinoma
6
Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoma
4
Urinary Bladder Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms by Site
3
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Gallbladder Neoplasms
2
Bile Duct Neoplasms
2
Vaccinia
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Resectable Intrahepatic Cholangiocarcinoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oropharyngeal Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Interventions
Cytarabine
5
Whole-Body Irradiation
3
Specimen Handling
3
Injections
3
CPX-351
3
Blood Specimen Collection
3
venetoclax
2
luspatercept
2
ivosidenib
2
fludarabine phosphate
2
fludarabine
2
decitabine and cedazuridine drug combination
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Melphalan
2
Liposomes
2
Idarubicin
2
Granulocyte Colony-Stimulating Factor
2
Gemtuzumab
2
Filgrastim
2
Daunorubicin
2
Cyclosporine
2
Cyclophosphamide
2
Busulfan
2
Biopsy
2
Azacitidine
2
tocilizumab
1
selinexor
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
durvalumab
×
30 days
×
Clear all
No trials found.